2020 Conference Reveal Seattle
Join us in the Seattle, Washington area for the 2020 National Patient Education Conference, July 17-19

Learn more >>

Stepping Out to Cure Scleroderma
Take a Step for Scleroderma

Find a "Stepping Out to Cure Scleroderma" walk/run near you today!

Click here to get started >>

Learn about how scleroderma affects the body
Know the Face of Scleroderma 2019 Homepage Banner
Increase awareness of the disease and the Scleroderma Foundation's mission of support, education, and research.

Tell your story of scleroderma

  • What is Scleroderma?
  • News

 

Know the Face of Scleroderma 2019

Who We Are

The Scleroderma Foundation is a federally qualified 501(c)(3) nonprofit dedicated to serving the needs of the scleroderma community.  Our primary goal is to raise funds and awareness for our three-fold mission of support, education and research.  All donations are qualified charitable donations to the fullest extent of the law.  Our federal tax identification number is 52-1375827.  All donations are gratefully accepted. 

What is Scleroderma?

Scleroderma, or systemic sclerosis, is a chronic connective tissue disease generally classified as one of the autoimmune rheumatic diseases. The word “scleroderma” comes from two Greek words: “sclero” meaning hard, and “derma” meaning skin. Hardening of the skin is one of the most visible manifestations of the disease.

Read more >>

Download Our Free Scleroderma Information Packet

Can’t download It? Have us mail you a copy!

Buzzworthy Reads>>

scleroderma body thumbnail vertical.jpg

See our 2018 GuideStar Gold Star profile
GuideStar Gold Star

 

 

News

Visit the eLetter Archive to read the stories behind these headlines.  Submit your email address to receive the eLetter every week.

eLetter #826; August 16, 2019

  • Conference Videos on YouTube
  • National Advocate of the Year
  • Preparing for an Emergency
  • Putting It Together: Ticket to Work’s Resume and Interview Tips; Wednesday, August 28, 3-4:30 p.m. ET
  • National Commission on Scleroderma and Fibrotic Diseases Act, H.R. 3446
  • Step Out and Be Part of the Cure
  • Research Grant Deadline: September 16
  • Clinical Trial Opportunity 
    • Safety and Tolerability Study of AVID200, a Novel TGF-beta 1 & 3 Inhibitor, in Patients with Diffuse Cutaneous Systemic Sclerosis

E-Newsletter Signup

Get the latest news.

Please leave this field empty

Our Sponsors